Consensus development meeting 1995: combined oral contraceptives and cardiovascular disease.The Consensus Statement issued after the Second European Conference on Sex Steroids and Metabolism, Amsterdam, November 1995-Reference-Cited by-同舟云学术

Consensus development meeting 1995: combined oral contraceptives and cardiovascular disease.The Consensus Statement issued after the Second European Conference on Sex Steroids and Metabolism, Amsterdam, November 1995

Published:1996-01 Issue:1 Volume:10 Page:1-5
ISSN:0951-3590
Container-title:Gynecological Endocrinology
language:en
Short-container-title:Gynecological Endocrinology

Author:

Helmehorst F. M.,Bloemenkamp k. W.M.

Publisher

Informa UK Limited

Subject

Obstetrics and Gynaecology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://www.tandfonline.com/doi/pdf/10.3109/09513599609041263

Reference7 articles.

1. Consensus Development Meeting: Metabolic aspects of oralcontraceptives of relevance for cardiovascular diseases*

2. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study

3. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease

4. Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components

5. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol;Contraception;2006-04

2. A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 μg of ethinylestradiol and 100 μg of levonorgestrel with 30 μg of ethinylestradiol and 100 μg of levonorgestrel;Contraception;2005-08

3. Comparative study of the effects of two once-a-month injectable contraceptives (Cyclofem® and Mesigyna®) and one oral contraceptive (Ortho-Novum 1/35®) on coagulation and fibrinolysis;Contraception;2003-09

4. Thrombophilias and gynaecology;Best Practice & Research Clinical Obstetrics & Gynaecology;2003-06

5. Genetic polymorphisms modify the response of factor VII to oral contraceptive use: an example of gene–environment interaction;Vascular Pharmacology;2002-08